



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7  
11/2/01

Applicant: Hoogenboom and Henderikx

Serial No.: 09/822,698

Filed: March 30, 2001

Entitled: MUCIN-1 SPECIFIC BINDING  
MEMBERS AND METHODS OF USE  
THEREOF

Examiner: (not yet assigned)

Art Unit: 1645

Attorney Docket No.: DYX-015.1 US

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

OCT 19 2001

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to 37 C.F.R. § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Foreign Patent Publications

EP-A-184187, published June 11, 1986.

GB 2188638A, published October 7, 1987.

EP-A-239400, published September 30, 1987.

EP-A-0120694, published October 3, 1984.

EP-A-0125023, published November 14, 1984.

PCT Publication No. WO 94/13804, published June 23, 1994.

Articles

Acres et al., *J. Immunother.*, 14: 136-143 (1993)

Adams et al., *Cancer Res.*, 53: 4026-4034 (1993)

Agrawal et al., *Mol. Med. Today*, 4: 397-403 (1998)

Agrawal et al., *Nat. Med.*, 4: 43-49 (1998)

- Apostolopoulos et al., *Nat. Med.*, 4: 315-320 (1998)
- Bagshawe et al., *Antibody, Immunoconjugates and Radiopharmaceuticals*, 4: 915-922 (1991)
- Becker et al., *Proc. Natl. Acad. Sci. USA*, 93: 7826-7831 (1996)
- Beverly et al., *Int. Immunol.*, 4: 661-671 (1992)
- Bird et al., *Science*, 242: 423-426 (1988)
- Boon et al., *Immunol. Today*, 18: 267-268 (1997)
- Burchell et al., *Cancer Res.*, 47: 5476-5482 (1987)
- de Haard et al., *Adv. Drug Del. Rev.*, 31: 5-31 (1998)
- de Haard et al., *J. Biol. Chem.*, 274: 18218-18230 (1999)
- Fan et al., *Clin. Diagn. Lab. Immunol.*, 5: 335-340 (1998)
- Fundamental Immunology, 4th ed. (Paul, William E., ed.) (Lippincott-Raven, Philadelphia, 1999), pages 58-60.
- Gendler et al., *J. Biol. Chem. Sep.*, 263: 12820-12823 (1988)
- Gillies et al., *Cancer Res.*, 59: 2159-2166 (1999)
- Gillies et al., *Proc. Natl. Acad. Sci. USA*, 89: 1428-1432 (1992)
- Gillis et al., *J. Immunol.*, 120: 2027-2032 (1978)
- Goldstein et al., *Biophys. J.*, 56: 955-966 (1989)
- Goldstein et al., *Immunol. Today*, 17: 77-80 (1996)
- Gong et al., *Proc. Natl. Acad. Sci. USA*, 95: 6279-6283 (1998)
- Goydos et al., *J. Surg. Res.*, 63: 298-304 (1996)
- Granowska et al., *Eur. J. Nucl. Med.*, 20: 483-489 (1993)
- Griffiths et al., *EMBO J.*, 12: 725-734 (1993)
- Gussow et al., *Nucleic Acids Res.*, 17: 4000 (1989)
- Heeg et al., *J. Immunol. Methods.*, 77: 237-246 (1985)
- Henderikx et al., *Cancer Res.*, 58: 4324-4332 (1998)
- Holliger and Winter, *Current Opinion Biotechnol.*, 4: 446-449 (1993)
- Holliger et al., *Proc. Natl. Acad. Sci. USA*, 90: 6444-6448 (1993)
- Hoogenboom et al., *Eur. J. Biochem.*, 260: 774-784 (1999)
- Hoogenboom et al., *Trends in Biotech.*, 15: 62-70 (1997)
- Huston et al., *Proc. Natl. Acad. Sci. USA*, 85: 5879-5883 (1988)
- Ioannides et al., *J. Immunol.*, 151: 3693-3703 (1993)
- Jerome et al., *Cancer Immunol Immunother.*, 43: 355-360 (1997)
- Jerome et al., *Cancer Res.*, 51: 2908-2916 (1991)
- Karanikas et al., *J. Clin. Invest.*, 100: 2783-2792 (1997)

Kieke et al., *Proc. Natl. Acad. Sci. USA*, 96: 5653-5656 (1999)  
Krambovitis et al., *J. Biol. Chem.*, 273: 10874-10879 (1998)  
Kramer et al., *J. Nucl. Med.*, 34: 1067-1074 (1993)  
Ledermann et al., *Int. J. Cancer*, 47: 659-664 (1991)  
Maraveyas et al., *Cancer Res.*, 55: 1060-1069 (1995)  
Mariani et al., *Cancer Res.*, 55: 5911s-5915s (1995)  
Marks et al., *J. Mol. Biol.*, 222: 581-597 (1991)  
McGuinness et al., *Nature Biotechnol.*, 14: 1149-1154 (1996)  
Melani et al., *Cancer Res.*, 58: 4146-4154 (1998)  
Miles et al., *Pharmacol. Ther.*, 82: 97-106 (1999)  
Naramura et al., *Immunol Lett.*, 39: 91-99 (1994)  
Paul et al., *Cancer Immunol. Immunother.*, 48: 22-28 (1999)  
Pecher et al., *Proc. Natl. Acad. Sci. USA*, 93: 1699-1704 (1996)  
Perkins et al., *Nucl. Med. Commun.*, 14: 578-586 (1993)  
Plunkett et al., *Cancer Treat. Rev.*, 24: 55-67 (1998)  
Reisfeld et al., *J. Clin. Lab. Anal.*, 10: 160-166 (1996)  
Roovers et al., *Br. J. Cancer*, 78: 1407-1416 (1998)  
Rosenberg et al., *Ann. Surg.*, 210: 474-485 (1989)  
Rousch et al., *Br. J. Pharmacol.*, 125: 5-16 (1998)  
Savage et al., *Br. J. Cancer*, 67: 304-310 (1993)  
Swallow et al., *Nature*, 328: 82-84 (1987)  
Traunecker et al., *EMBO J.*, 10: 3655-3659 (1991)  
Van Antwerp et al., *Biotechnol. Prog.*, 16: 31-37 (2000)  
Vaughan et al., *Nat. Biotechnol.*, 14: 309-314 (1996)  
Velders et al., *Br. J. Cancer*, 78: 478-483 (1998)  
von Mensdorff-Pouilly et al., *Tumor Biol.*, 19: 186-195 (1998)  
Ward, et al., *Nature*, 341: 544-546 (1989)  
Wittrup, *Trends In Biotechnol.*, 17: 423-424 (1999)

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

*Thomas R. Berka*

Leon R. Yankwich, Reg No. 30,237  
Thomas R. Berka, Ph.D. Reg. No 39,606  
Attorney for Applicants  
YANKWICH & ASSOCIATES  
130 Bishop Allen Drive  
Cambridge, Massachusetts 02139  
telephone: (617) 491-4343  
telefax: (617) 491-8801

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Priority Mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

October 10, 2001  
Date

Stephanie L. Leicht  
Stephanie L. Leicht